keyword
MENU ▼
Read by QxMD icon Read
search

Venlafaxine XR

keyword
https://www.readbyqxmd.com/read/28982121/short-term-efficacy-and-tolerability-of-venlafaxine-extended-release-in-adults-with-generalized-anxiety-disorder-without-depression-a-meta-analysis
#1
Xinyuan Li, Lijun Zhu, Yingying Su, Shaokuan Fang
BACKGROUND: Although efficacy of venlafaxine extended release (XR) for generalized anxiety disorder (GAD) has been reported in previous analyses in 2002 and 2004, the sample size was rather small and estimate of safety or tolerability was not clear. The present analysis had the advantage of large sample size and provided evidence for tolerability. METHODS: Literature databases were searched, including Pubmed, Embase, Cochrane Central Register of Controlled Trials, Web of science and clinical trials...
2017: PloS One
https://www.readbyqxmd.com/read/28437668/genome-wide-association-study-of-treatment-response-to-venlafaxine-xr-in-generalized-anxiety-disorder
#2
Jeesun Jung, Elisabeth A Tawa, Christine Muench, Allison D Rosen, Karl Rickels, Falk W Lohoff
We conducted the first genome-wide association study (GWAS) in Generalized Anxiety Disorder (GAD) to identify potential predictors of venlafaxine XR treatment outcome. Ninety-eight European American patients participated in a venlafaxine XR clinical trial for GAD, with Hamilton Anxiety Scale (HAM-A) response/remission at 24 weeks as the primary outcome measure. All participants were genotyped with the Illumina PsychChip, and 266,820 common single nucleotide polymorphisms (SNPs) were analyzed. Although no SNPs reached genome-wide significance, 8 SNPs were marginally associated with treatment response/remission and HAM-A reduction at week 12 and 24 (p<0...
April 14, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28087352/engineering-hot-melt-extruded-solid-dispersion-for-controlled-release-of-hydrophilic-drugs
#3
Shuli Zhang, Xuan Meng, Zheng Wang, Aiping Fan, Guocheng Wang, Yanjun Zhao, Yu Tang
It is often challenging to precisely manipulate the release behavior of hydrophilic drugs that is believed to be crucial for a satisfactory therapeutic outcome. The aim of this work was to regulate the dissolution of hydrophilic drug from hot-melt extruded solid dispersion via rational screening of the pore-forming agents. Venlafaxine hydrochloride and Compritol® 888 ATO was selected as the model drug and carrier excipient, respectively. Hydrophilic polyethylene glycol (PEG 6000) and polyvinylpyrolidone (PVP K30) were chosen as the transient pore-forming agents...
March 30, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27972892/cost-utility-analysis-evaluating-vortioxetine-versus-venlafaxine-xr-and-agomelatine-in-the-treatment-of-major-depressive-disorder-in-taiwan
#4
M Brignone, K Atsou, C Reynaud-Mougin, W Chen, D Milea
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27837032/treatment-of-neuropathic-pain-with-venlafaxine-a-systematic-review
#5
REVIEW
Rohit Aiyer, Robert L Barkin, Anurag Bhatia
OBJECTIVE : To investigate the efficacy of venlafaxine for neuropathic pain and review literature to determine if the medication provides adequate neuropathic pain relief. METHODS : Literature was reviewed on MEDLINE using various key words. These key words include: "venlafaxine and pain," "venlafaxine ER and pain," "venlafaxine XR and pain," "venlafaxine and neuropathic pain," "venlafaxine and neuropathy," "SSRI and neuropathic pain," "SSRI and neuropathy," "SNRI and neuropathic pain," "SNRI and neuropathy," "serotonin reuptake inhibitor and neuropathic pain," "serotonin reuptake inhibitor and neuropathy," "serotonin norepinephrine reuptake inhibitor and neuropathic pain" and "serotonin norepinephrine reuptake inhibitor and neuropathy...
November 11, 2016: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/27747715/coma-after-quetiapine-fumarate-intentional-overdose-in-a-71-year-old-man-a-case-report
#6
S Gibiino, A Trappoli, B Balzarro, A R Atti, D De Ronchi
A 71-year-old man developed coma with severe respiratory failure, hypotension, and tachycardia induced by the intentional ingestion of quetiapine fumarate extended release (XR) 20 g. At the time, he had been treated for bipolar depression with venlafaxine 75 mg/day, lamotrigine 100 mg/day, pregabalin 75 mg/day, and quetiapine XR 400 mg/day for approximately 1 year. Comorbidities were hypertension treated with metoprolol, diabetes mellitus type 2 treated with metformin, and benign prostatic hyperplasia treated with silodosin...
December 2015: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/27712567/development-and-optimization-of-controlled-porosity-osmotic-tablets-of-lamotrigine-solid-dispersion
#7
Gayatri C Patel, Megha Kasarwala
BACKGROUND: The purpose of this study was to investigate the application of a controlled porosity osmotic tablet (CPOT) utilizing solid dispersion (SD) of poorly soluble drug. The patents on Cyclobenzaprine HCl (US4968507 A) and Venlafaxine salts (EP 2085078 A1) helped in selection of drug and polymers. METHOD: The SDs having different ratio of drug to carrier (PVP K 30) were prepared by kneading method and optimized. Effect of three independent variables, total amount of osmogen (mannitol& potassium chloride), total amount of polymer (polyethylene oxide WSR 301, hydroxy propyl methyl cellulose K100 M), and polymer1: polymer 2 ratio was investigated using Box Behnken design...
October 4, 2016: Recent Patents on Drug Delivery & Formulation
https://www.readbyqxmd.com/read/27680105/cost-utility-analysis-of-vortioxetine-versus-agomelatine-bupropion-sr-sertraline-and-venlafaxine-xr-after-treatment-switch-in-major-depressive-disorder-in-finland
#8
COMPARATIVE STUDY
Erkki Soini, Taru Hallinen, Mélanie Brignone, Rosanne Campbell, Françoise Diamand, Sandrine Cure, Maria Aalto-Setälä, Natalya Danchenko, Hannu Koponen, Katarzyna Kolasa
BACKGROUND: To assess the cost-utility of vortioxetine versus relevant comparators (agomelatine, bupropion SR, sertraline, and venlafaxine XR) in the finnish setting in major depressive disorder (MDD) patients with inadequate response to selective serotonin- /serotonin-norepinephrine reuptake inhibitors. METHODS: A one-year analysis was conducted using a decision tree with a Markov state transition component. The health states were remission, relapse and recovery...
June 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27538352/impact-of-prior-treatment-on-remission-of-late-life-depression-with-venlafaxine-and-subsequent-aripiprazole-or-placebo-augmentation
#9
Jonathan H Hsu, Benoit H Mulsant, Eric J Lenze, Jordan F Karp, Helen Lavretsky, Steven P Roose, Charles F Reynolds, Daniel M Blumberger
OBJECTIVE: Treatment history can inform clinical decisions about subsequent treatment choices. The authors examined the impact of prior antidepressant treatment on treatment outcomes with venlafaxine only and then with augmentation with aripiprazole or placebo in depressed older adults. METHODS: The authors analyzed outcome data from a randomized, placebo-controlled clinical trial of aripiprazole augmentation in depressed older adults. The study consisted of an open-label lead-in phase with venlafaxine XR, followed by a placebo-controlled phase of aripiprazole augmentation...
October 2016: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/27289476/the-clinical-and-cost-effectiveness-of-vortioxetine-for-the-treatment-of-a-major-depressive-episode-in-patients-with-failed-prior-antidepressant-therapy-a-critique-of-the-evidence
#10
REVIEW
James Lomas, Alexis Llewellyn, Marta Soares, Mark Simmonds, Kath Wright, Alison Eastwood, Stephen Palmer
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of vortioxetine (Lundbeck) to submit clinical and cost-effectiveness evidence for vortioxetine for the treatment of major depressive episodes (MDEs), as part of the Institute's Single Technology Appraisal (STA) process. The Centre for Reviews and Dissemination and Centre for Health Economics at the University of York were commissioned to act as the independent Evidence Review Group (ERG). This article provides a description of the company submission, the ERG review and the resulting NICE guidance TA367 issued in November 2015...
September 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27162147/treatment-emergent-suicidal-ideation-in-depressed-older-adults
#11
Pilar Cristancho, Brendan O'Connor, Eric J Lenze, Daniel M Blumberger, Charles F Reynolds, David Dixon, Benoit H Mulsant
BACKGROUND: Treatment-Emergent Suicidal Ideation (TESI) in older adults is poorly understood. We characterized TESI in older depressed adults during treatment with venlafaxine and explored whether TESI is related to antidepressant exposure versus dimensions of the psychiatric illness. We examined the relationship among medication exposure, onset of TESI, and clinical characteristics. METHODS: We analyzed data on 233 clinical trial participants with major depression and no baseline suicidal ideation who were treated for up to 12 weeks with venlafaxine XR (target dose: 150-300 mg/day)...
June 2017: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/27109856/assessment-of-the-relationship-of-spiritual-well-being-to-depression-and-quality-of-life-for-persons-with-spinal-cord-injury
#12
Catherine S Wilson, Martin Forchheimer, Allen W Heinemann, Anne Marie Warren, Cheryl McCullumsmith
OBJECTIVE: This study sought to describe the association between spiritual well-being, demographic characteristics, quality of life (QOL) and depressive symptoms following spinal cord injury (SCI). We hypothesized QOL and depressed mood would both be explained by extent of spiritual well-being, and meaning-focused (M&P) spirituality would have a stronger impact than faith-focused spirituality. METHODS: 210 individuals with SCI were screened as part of a randomized control trial of venlafaxine XR for major depressive disorder (MDD)...
April 25, 2016: Disability and Rehabilitation
https://www.readbyqxmd.com/read/27088461/second-order-peer-reviews-of-clinically-relevant-articles-for-the-physiatrist-is-venlafaxine-xr-effective-for-major-depression-in-people-with-spinal-cord-injury
#13
Sunil Sabharwal, Dinesh Kumbhare
No abstract text is available yet for this article.
August 2016: American Journal of Physical Medicine & Rehabilitation
https://www.readbyqxmd.com/read/26899588/randomized-controlled-study-of-early-medication-change-for-non-improvers-to-antidepressant-therapy-in-major-depression-the-emc-trial
#14
RANDOMIZED CONTROLLED TRIAL
André Tadić, Daniel Wachtlin, Mathias Berger, Dieter F Braus, Dietrich van Calker, Norbert Dahmen, Nadine Dreimüller, Alice Engel, Stanislav Gorbulev, Isabella Helmreich, Anne-Katrin Kaiser, Kai Kronfeld, Konrad F Schlicht, Oliver Tüscher, Stefanie Wagner, Christoph Hiemke, Klaus Lieb
Patients with Major Depressive Disorder (MDD) and no improvement after two weeks of antidepressant pharmacotherapy have a high risk of treatment failure. The aim of the study was to determine whether an early medication change (EMC) strategy is superior to a guideline-based treatment in MDD patients without improvement after two weeks of antidepressant pharmacotherapy. Eight-hundred-and-eighty-nine patients with MDD were enrolled, 879 patients received the SSRI escitalopram. Of those, 192 patients had no improvement, defined as a reduction of < 20% on the Hamilton Depression Rating Scale (HAMD-17) after 14 days of treatment, and were randomly assigned to open treatment with the EMC strategy (n = 97; venlafaxine XR for study days 15-56; in case of sustained non-improvement on day 28, lithium augmentation for days 29-56) or TAU (n = 95; escitalopram continuation; non-responders on day 28 were switched to venlafaxine XR for four weeks, i...
April 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/26864543/the-safety-and-tolerability-of-vortioxetine-analysis-of-data-from-randomized-placebo-controlled-trials-and-open-label-extension-studies
#15
David S Baldwin, Lambros Chrones, Ioana Florea, Rebecca Nielsen, George G Nomikos, William Palo, Elin Reines
The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 randomized, double-blind placebo-controlled short-term studies in major depressive disorder: six with an active reference. Symptoms following discontinuation were assessed through the Discontinuation-Emergent Signs and Symptoms checklist in three studies. Long-term (⩽52 weeks) tolerability was evaluated in five open-label extension studies...
March 2016: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/26859610/evaluating-the-psychometric-properties-and-responsiveness-to-change-of-3-depression-measures-in-a-sample-of-persons-with-traumatic-spinal-cord-injury-and-major-depressive-disorder
#16
RANDOMIZED CONTROLLED TRIAL
Ryan T Williams, Allen W Heinemann, Holly Demark Neumann, Jesse R Fann, Martin Forchheimer, Elizabeth J Richardson, Charles H Bombardier
OBJECTIVES: To compare the measurement properties and responsiveness to change of the Patient Health Questionnaire-9 (PHQ-9), the Hopkins Symptom Checklist-20 (HSCL-20), and the Hamilton Depression Rating Scale (HAM-D) in people with spinal cord injury (SCI) diagnosed with major depressive disorder (MDD). DESIGN: Secondary analysis of depression symptoms measured at 6 occasions over 12 weeks as part of a randomized controlled trial of venlafaxine XR for MDD in persons with SCI...
June 2016: Archives of Physical Medicine and Rehabilitation
https://www.readbyqxmd.com/read/26708830/trajectories-of-suicidal-ideation-in-depressed-older-adults-undergoing-antidepressant-treatment
#17
John Kasckow, Ada Youk, Stewart J Anderson, Mary Amanda Dew, Meryl A Butters, Megan M Marron, Amy E Begley, Katalin Szanto, Alexander Y Dombrovski, Benoit H Mulsant, Eric J Lenze, Charles F Reynolds
UNLABELLED: Suicide is a public health concern in older adults. Recent cross sectional studies suggest that impairments in executive functioning, memory and attention are associated with suicidal ideation in older adults. It is unknown whether these neuropsychological features predict persistent suicidal ideation. We analyzed data from 468 individuals ≥ age 60 with major depression who received venlafaxine XR monotherapy for up to 16 weeks. We used latent class growth modeling to classify groups of individuals based on trajectories of suicidal ideation...
February 2016: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/26674366/eeg-abnormalities-are-associated-with-poorer-depressive-symptom-outcomes-with-escitalopram-and-venlafaxine-xr-but-not-sertraline-results-from-the-multicenter-randomized-ispot-d-study
#18
RANDOMIZED CONTROLLED TRIAL
Martijn Arns, Evian Gordon, Nash N Boutros
Rationale Limited research is available on electrophysiological abnormalities such as epileptiform EEG or EEG slowing in depression and its association with antidepressant treatment response. Objectives We investigated the association between EEG abnormalities and antidepressant treatment response in the international Study to Predict Optimized Treatment in Depression (iSPOT-D). Methods Of 1008 participants with major depressive disorder randomized to escitalopram, sertraline, or venlafaxine-XR, 622 completed 8 weeks of treatment per protocol...
January 2017: Clinical EEG and Neuroscience: Official Journal of the EEG and Clinical Neuroscience Society (ENCS)
https://www.readbyqxmd.com/read/26641142/cost-effectiveness-of-vortioxetine-versus-venlafaxine-extended-release-in-the-treatment-of-major-depressive-disorder-in-south-korea
#19
COMPARATIVE STUDY
Sang-Eun Choi, Mélanie Brignone, Seong Jin Cho, Hong Jin Jeon, Rangrhee Jung, Rosanne Campbell, Clément Francois, Dominique Milea
OBJECTIVE: To assess the cost-effectiveness of vortioxetine versus venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea. METHODS: A 1-year cost-effectiveness analysis from a limited societal perspective was performed using a combined model consisting of a decision-tree and a Markov model. Patients entered the model when initiating or switching antidepressant treatment following inadequate response to previous treatment. Remission, relapse and recovery were the main health states...
October 2016: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/26637048/efficacy-and-tolerability-of-switching-therapy-to-vortioxetine-versus-other-antidepressants-in-patients-with-major-depressive-disorder
#20
REVIEW
Mélanie Brignone, Françoise Diamand, Caroline Painchault, Shweta Takyar
OBJECTIVES: To assess the relative efficacy and tolerability of vortioxetine against different antidepressant monotherapies in patients with major depressive disorder (MDD) with inadequate response to selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) therapy. METHODS: A systematic search was conducted for monotherapy studies in patients with MDD with inadequate response to first-line therapy. Treatments included SSRIs, SNRIs, and other antidepressants...
2016: Current Medical Research and Opinion
keyword
keyword
50551
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"